Actuarial disease-free survival after prostate cancer brachytherapy using interactive techniques with biplane ultrasound and fluoroscopic guidance.
暂无分享,去创建一个
J M Collins | G. Swanson | R. Navickis | M. Wilkes | G P Swanson | J. Kriegshauser | T R Larson | G L Grado | C S Balch | M M Grado | J S Kriegshauser | R J Navickis | M M Wilkes | G. Grado | M. Wilkes | R. Navickis | J. Collins | T. Larson | C. Balch | M. M. Grado | Carrie S. Balch | Thayne R. Larson | Mary M. Grado | Gordon L. Grado | Joseph M. Collins | G. P. Swanson
[1] Hanks Ge. Treatment of early stage prostate cancer: radiotherapy. , 1994 .
[2] F. Critz,et al. Prostate specific antigen‐monitored combination radiotherapy for patients with prostate cancer. I‐125 implant followed by external‐beam radiation , 1995, Cancer.
[3] A. K. Levinson,et al. The PSA nadir that indicates potential cure after radiotherapy for prostate cancer. , 1997, Urology.
[4] J. Blasko,et al. Brachytherapy for prostate cancer , 1995, CA: a cancer journal for clinicians.
[5] K. Wallner,et al. 103Pd brachytherapy and external beam irradiation for clinically localized, high-risk prostatic carcinoma. , 1996, International journal of radiation oncology, biology, physics.
[6] L. Blank,et al. Treatment of localized prostatic carcinoma using the transrectal ultrasound guided transperineal implantation technique. , 1992, European urology.
[7] J. Blasko,et al. Transperineal ultrasound-guided implantation of the prostate: morbidity and complications. , 1991, Scandinavian journal of urology and nephrology. Supplementum.
[8] J. Payne,et al. Percutaneous iodine-125 seed implantation for carcinoma of the prostate. , 1995, The Australian and New Zealand journal of surgery.
[9] L. Anderson,et al. Dosimetry of interstitial brachytherapy sources: Recommendations of the AAPM Radiation Therapy Committee Task Group No. 43 , 1995 .
[10] L L Anderson,et al. A nomograph for permanent implants of palladium-103 seeds. , 1993, International journal of radiation oncology, biology, physics.
[11] A. Zietman,et al. Radical radiation therapy in the management of prostatic adenocarcinoma: the initial prostate specific antigen value as a predictor of treatment outcome. , 1994, The Journal of urology.
[12] J. Blasko,et al. Interstitial iodine‐125 radiation without adjuvant therapy in the treatment of clinically localized prostate carcinoma , 1997, Cancer.
[13] P. Unger,et al. Prostate specific antigen findings and biopsy results following interactive ultrasound guided transperineal brachytherapy for early stage prostate carcinoma , 1996, Cancer.
[14] M. Zelefsky,et al. Long-term results of retropubic permanent 125iodine implantation of the prostate for clinically localized prostatic cancer. , 1997, The Journal of urology.
[15] A. Pollack,et al. Prostate specific antigen doubling time and disease relapse after radiotherapy for prostate cancer , 1994, Cancer.
[16] J. Gottesman,et al. Failure of open radioactive 125iodine implantation to control localized prostate cancer: a study of 41 patients. , 1991, The Journal of urology.
[17] A T Cockett,et al. Transurethral prostatectomy: practice aspects of the dominant operation in American urology. , 1989, The Journal of urology.
[18] Samuel Hellman,et al. Important advances in oncology , 1991 .
[19] J. Blasko,et al. Prostate specific antigen based disease control following ultrasound guided 125iodine implantation for stage T1/T2 prostatic carcinoma. , 1995, The Journal of urology.
[20] K. Rosenzweig,et al. Prostate specific antigen following radiotherapy for local prostate cancer. , 1995, The Journal of urology.
[21] J. Roy,et al. Short-term freedom from disease progression after I-125 prostate implantation. , 1994, International journal of radiation oncology, biology, physics.
[22] J. Payne,et al. Original Articles: Prostate Cancer , 1995 .
[23] J. Blasko,et al. External beam irradiation with palladium-103 implantation for prostate carcinoma , 1994 .
[24] J. Blasko,et al. A method for implementing the American Association of Physicists in Medicine Task Group-43 dosimetry recommendations for 125I transperineal prostate seed implants on commercial treatment planning systems. , 1997, International journal of radiation oncology, biology, physics.
[25] Peter D. Grimm,et al. Use of Transrectal Ultrasound in Transperineal 125Iodine Seeding for Prostate Cancer: Methodology , 1989 .
[26] P. Schellhammer,et al. Prostate-specific antigen to determine progression-free survival after radiation therapy for localized carcinoma of prostate. , 1993, Urology.
[27] D. Beyer,et al. Biochemical disease-free survival following 125I prostate implantation. , 1997, International journal of radiation oncology, biology, physics.
[28] G. Farrow,et al. Pathologic differentiation and prognosis of prostatic carcinoma. , 1969, JAMA.
[29] S. Cha,et al. Prostate-specific antigen as a pretherapy prognostic factor in patients treated with radiation therapy for clinically localized prostate cancer. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] S. Stokes,et al. Transperineal ultrasound-guided radioactive seed implantation for organ-confined carcinoma of the prostate. , 1997, International journal of radiation oncology, biology, physics.
[31] G. Swanson,et al. Definitive therapy for prostate carcinoma: Mayo Clinic results at 15 years after treatment. , 1994, The British journal of radiology.
[32] J Roy,et al. Tumor control and morbidity following transperineal iodine 125 implantation for stage T1/T2 prostatic carcinoma. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] B. Chauvet,et al. Prostate-specific antigen decline: a major prognostic factor for prostate cancer treated with radiation therapy. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] A. D'Amico,et al. Role of interstitial radiotherapy in the management of clinically organ-confined prostate cancer: the jury is still out. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] A. Hanlon,et al. Prostate specific antigen nadir following external beam radiation therapy for clinically localized prostate cancer: the relationship between nadir level and disease-free survival. , 1996, The Journal of urology.
[36] V. Althof,et al. Variation in prostate position relative to adjacent bony anatomy. , 1996, International journal of radiation oncology, biology, physics.
[37] K. Wallner,et al. Low risk of urinary incontinence following prostate brachytherapy in patients with a prior transurethral prostate resection. , 1997, International journal of radiation oncology, biology, physics.
[38] J Roy,et al. Short-term morbidity from CT-planned transperineal I-125 prostate implants. , 1993, International journal of radiation oncology, biology, physics.
[39] R. Stock,et al. Brachytherapy for prostate cancer: real-time three-dimensional interactive seed implantation. , 1995, Techniques in urology.
[40] I. Kaplan,et al. Prostate specific antigen after external beam radiotherapy for prostatic cancer: followup. , 1993, The Journal of urology.
[41] Blasko,et al. Brachytherapy and Organ Preservation in the Management of Carcinoma of the Prostate. , 1993, Seminars in radiation oncology.
[42] S. Kandzari,et al. Iodine 125 seed implants for prostatic carcinoma. Five- and ten-year follow-up. , 1993, Urology.